title: Saccadic peak velocity and EEG as end-points for a serotonergic challenge test.
abstract: We previously reported that a single dose of the serotonin receptor agonist meta-chlorophenylpiperazine increased the peak velocity of saccadic eye movements and decreased low-frequency electroencephalographic activity.
  
  
  METHODS
  We administered a single dose of the serotonin releaser dexfenfluramine in a double blind, placebo controlled randomised cross-over design and measured saccadic eye movements and EEG every hour up to 6 h. Subjects were 62 males (18-30 years) with a history of no, moderate or heavy use of ecstasy tablets.
  
  
  RESULTS
  Dexfenfluramine increased saccadic peak velocity and decreased alpha, delta and theta electroencephalographic activity, the latter predominantly in heavy users of ecstasy.
  
  
  CONCLUSIONS
  This study supports the idea that saccadic peak velocity and EEG can be useful endpoints of a serotonergic challenge. This could be an important anatomical extension of these end-points, which until now were limited to the effect on hypothalamic serotonergic projections.
authors.affiliation: Centre for Human Drug Research, Leiden, The Netherlands. harm.gijsman@doctors.org.uk
authors.forename: Harm J
authors.initials: HJ
authors.lastname: Gijsman
authors.forename: Joop M A
authors.initials: JM
authors.lastname: van Gerven
authors.forename: Robbert Jan
authors.initials: RJ
authors.lastname: Verkes
authors.forename: Rik C
authors.initials: RC
authors.lastname: Schoemaker
authors.forename: Monique S M
authors.initials: MS
authors.lastname: Pieters
authors.forename: Ed J M
authors.initials: EJ
authors.lastname: Pennings
authors.forename: Trees J
authors.initials: TJ
authors.lastname: Hessing
authors.forename: Adam F
authors.initials: AF
authors.lastname: Cohen
mesh_terms: D000293:Adolescent; D000328:Adult; D018592:Cross-Over Studies; D020372:Dexfenfluramine / Q000493:pharmacokinetics / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004569:Electroencephalography; D006213:Hallucinogens; D006801:Humans; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D009642:Norfenfluramine / Q000378:metabolism; D012438:Saccades / Q000187:drug effects*; D012701:Serotonin / Q000502:physiology*; D017366:Serotonin Receptor Agonists / Q000493:pharmacokinetics / Q000494:pharmacology*; D019966:Substance-Related Disorders / Q000503:physiopathology
chemical_list: D006213:Hallucinogens; D017366:Serotonin Receptor Agonists; D009642:Norfenfluramine; D012701:Serotonin; D020372:Dexfenfluramine; D018817:N-Methyl-3,4-methylenedioxyamphetamine